Navigation Links
Investigational Study Demonstrated a Re-Establishment of Clinical,Improvement with Orencia (Abatacept) in Children with Juvenile,Idiopathic Arthritis upon Re-Introduction of Therapy

BARCELONA, Spain, June 15, 2007 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company today announced results regarding the efficacy and safety of ORENCIA(R) (abatacept) from the open-label phase of an ongoing investigational study in children with juvenile idiopathic arthritis (JIA) who have had an inadequate response to one or more disease-modifying anti- rheumatic drugs (DMARDs), such as methotrexate (MTX) or tumor necrosis factor (TNF) antagonists. The results demonstrated that, after a study protocol- mandated withdrawal period of up to six months, the re-introduction of ORENCIA was associated with a re-establishment of clinical improvement as measured by the of Rheumatology's Pediatric (ACR Pedi) criteria for improvement in children with JIA. The data will be presented tomorrow at the Annual Congress of the European League Against Rheumatism.

"Children with JIA can have long periods of inactive disease and clinical remission, which makes it important to study the efficacy and safety of re- starting a treatment after a withdrawal period," said Edward H. Giannini, M.Sc., Dr.P.H., Professor of Pediatrics, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, OH, co-principal investigator of the study. "The results of this investigational study suggest that, in these children with JIA who had disease flares while taking placebo during the mandated withdrawal phase, resuming therapy with ORENCIA was associated with a re-establishment of clinical improvement."

The study, designed to assess the efficacy, safety and tolerability of ORENCIA in children and adolescents (ages 6-17 years) with JIA, consisted of three periods: a four-month open-label lead-in treatment period in which all participants received ORENCIA and both a clinical response and safety were assessed (Period A), a six-month randomized double-blind withdrawal phase where responders received either ORENCIA(R) (abatac
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
5. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
6. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
10. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
11. Investigational Study Evaluates the Effectiveness of Aripiprazole in Adolescents With Schizophrenia

Post Your Comments:
(Date:11/20/2009)...wire-FirstCall/ -- Smith & Nephew ( SNN, LSE: ...he signing of a technology development contract wi...y lead to the creation of a fracture fixation syst...limbs of soldiers who sustain battlefield injuries...rojects Agency (DARPA), the central research and d...
(Date:11/19/2009)...e/ -- In response to an ever-increasing number of ..., Operation Pangea II, involving 24 countries, was...nization,s International Medical Products Anti-Cou...ngers of buying medicines online. ,, The week l...sts and the seizure of thousands of potentially ha...
(Date:11/19/2009).../ -- Riverain Medical announced today that the com...cal imaging distributor Christie Group to offer So...ay CAD. The exclusive agreement will bring Dayton,...adian market through Christie Group,s established ...ed Chest Imaging increases the clarity of digital ...
Breaking Medicine Technology:Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 2Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 3Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 4International Operation Combats Online Supply of Counterfeit and Illegal Medicines 2Riverain Medical Partners With The Christie Group In Canada To Offer SoftView Enhanced Chest Imaging and OnGuard Chest X-Ray CAD Technologies 2Finance Committee Begins Markup Lab Fee Converted to Medicare Cut 14238 1Max Neeman International to Open Phase I IIa Unit 14233 1Max Neeman International to Open Phase I IIa Unit 14233 2Medicinal products susceptible to dose dumping should be fully tested 58148 1
... Analysis Demonstrates Robust, Highly Statisticall...umab Compared to Rebif(R), CAMBRIDGE, Mass., Oct....nounced that top-line, three-year data from a,comp... with Rebif(R),(interferon beta- 1a) for the treat...kend at the 23rd Congress of the European Committe...
...ata to be Submitted for Presentation at 2007 San A...mposium, REDWOOD CITY, Calif., Oct. 11 Genomic H...aging results from a study of,Oncotype DX in postm...or,positive breast cancer conducted by the Southwe...ute clinical trials cooperative group. Oncotype DX...
Other Medicine Technology:Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis 2Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis 3Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis 4Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis 5Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis 6Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis 7Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients 2Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients 3
(Date:11/20/2009)...ov. 20 The following is...of the Nevada Health Care Association: ,, "The ... thanks Senate Majority Leader Harry Reid for his ...rd our goal of protecting every Nevada seniors, on...serving the strength and viability of our state,s ...
(Date:11/20/2009)...readings in children with chronic kidney disease o...or,s office visits increasing a child,s risk for ... Johns Hopkins Children,s Center and other institu...the Journal of American Society of Nephrology. ,...s obtained during regular doctor visits to reading...
(Date:11/20/2009)...ne-third buying 90-day supply, study finds , ...a three-month supply of prescription drugs is up t..., according to a new study. , U.S. researchers ... between 2000 and 2005, and found that patients wh...th supply saved an average 29 percent in out-of-po...
(Date:11/20/2009)... Bread addresses increased food insecurity as many...Newswire-USNewswire/ -- Project Bread, the state,s...s from its upcoming annual status report on hunger...ibed in this report, caused by high unemployment, ...ling with hunger. Food insecurity has found its wa...
(Date:11/20/2009)..., La., Nov. 20 The ... warned that Louisianians could experience higher ...sals being considered by Congress should become la...fficer for LAHP, "Louisiana health plans have supp...eginning of the national debate. Our plans have o...
Breaking Medicine News(10 mins):Health News:High blood pressure easy to miss in children with kidney disease 2Health News:Three-Month Supply Lowers Drug Costs 2Health News:554,000 in Massachusetts Struggle to Put Food on the Table 2Health News:554,000 in Massachusetts Struggle to Put Food on the Table 3Health News:554,000 in Massachusetts Struggle to Put Food on the Table 4Health News:Congressional Health Care Reform Proposals Would Make Health Care More Expensive, Reduce Benefits for Louisianians 2
...difference in chemotherapy treatment; some critics...t. 8 (HealthDay News) -- A 2003 overhaul of Medica... for their services did not alter cancer patients,...rapy treatments to begin and traveling the same di...
...al in Northeast Ohio to make quality and safety li...ron City,Hospital has been named a "Leapfrog Top H...Ohio and one of just 33 adult hospitals in the nat...hat,assesses hospital quality and safety. Accordi...
...MFIELD, Conn., Oct. 8, 2007 /PRNewswire-FirstCall/...y concern among America,s,local governments, most ...management programs targeting their stated top hea...d sponsored by leading,employee benefits carrier, ...
...olon cancer is proving much more convenient than t...and a study of almost 2,000 patients has shown it ...sease. , Standard chemotherapy can be incredibly...week for the injections and then have three weeks ...
...es Epidemic Opportunity, BRENTWOOD, Tenn., Oct. 8...red a growth equity investment of $50 million from...s investment, NEA General,Partners Chip Linehan an...supplies market," said Richard Pinson, Simplex,Cha...
...d soul, PAGOSA SPRINGS, Colo., Oct. 8 1.1 billio...; another 1.5 billion don,t have,adequate sanitati...he world,s poorest people access to,safe water and...na,s northern regions are acutely deprived, with o...
Other Medicine News:Health News:Medicare Changes Didn't Alter Cancer Care 2Health News:Medicare Changes Didn't Alter Cancer Care 3Health News:Medicare Changes Didn't Alter Cancer Care 4Health News:Summa Health System's Akron City Hospital Named 'Leapfrog Top Hospital' for 2007 2Health News:ICMA/CIGNA Survey: U.S. Cities and Counties Begin to Focus on Health Risks and Costs 2Health News:ICMA/CIGNA Survey: U.S. Cities and Counties Begin to Focus on Health Risks and Costs 3Health News:ICMA/CIGNA Survey: U.S. Cities and Counties Begin to Focus on Health Risks and Costs 4Health News:Simplex Diabetic Supply, Inc. Secures $50 Million in Growth Equity from New Enterprise Associates 2Health News:Make a Difference This Holiday Season 2
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
Medicine Products: